Focused On-demand Library for F-box/WD repeat-containing protein 11

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9UKB1

UPID:

FBW1B_HUMAN

Alternative names:

F-box and WD repeats protein beta-TrCP2; F-box/WD repeat-containing protein 1B; Homologous to Slimb protein

Alternative UPACC:

Q9UKB1; B2RC98; Q9P2S8; Q9P2S9; Q9Y4C6

Background:

F-box/WD repeat-containing protein 11, also known as FBXW11, plays a crucial role in cellular processes by mediating the ubiquitination and subsequent proteasomal degradation of target proteins. It is involved in various signaling pathways, including Wnt signaling and NF-kappa-B activation, and regulates cell cycle, oxidative stress response, and viral infection defense mechanisms.

Therapeutic significance:

FBXW11's involvement in Neurodevelopmental, jaw, eye, and digital syndrome highlights its potential as a therapeutic target. Understanding the role of FBXW11 could open doors to potential therapeutic strategies for this syndrome and other related conditions.